Table 2 Prior therapy for early breast cancer and metastatic breast cancer
Prior therapy for EBC | All patients(n = 211) | 1st line(n = 85) | 2nd line(n = 78) | ≥ 3rd line(n = 48) |
|---|---|---|---|---|
 Neoadjuvant CHT | 36(17.1) | 17(20.0) | 14(17.9) | 5(10.4) |
 Surgery | 173(82.0) | 62(72.9) | 69(88.5) | 42(87.5) |
 Adjuvant CHT | 139(65.9) | 51(60) | 49(62.8) | 39(81.3) |
 Adjuvant RT | 98(46.4) | 37(43.5) | 35(44.9) | 26(54.2) |
 Adjuvant ET | 128(60.7) | 45(52.9) | 48(62.8) | 34(70.8) |
  SERM | 66(51.6) | 22(47.8) | 25(52.1) | 19(55.9) |
  AI | 62(48.4) | 24(52.2) | 23(47.9) | 15(44.1) |
   Letrozole | 35(27.3) | 13(28.3) | 10(20.8) | 12(35.2) |
   Anatrozole | 5(3.9) | 2(4.3) | 1(2.2) | 2(5.9) |
   Exemestane | 13(10.2) | 4(8.7) | 8(16.7) | 1(2.9) |
   NA | 9(7.0) | 5(10.9) | 4(8.7) | - |
Prior therapy for MBC | Â | Â | Â | Â |
 Prior CHT for MBC | 82(38.9) | 7(8.2) | 38(48.7) | 37(77.1) |
 Prior ET for MBC | 63(29.9) | - | 30(38.5) | 33(68.8) |
  SERM | 4(6.3) | - | 3(10.0) | 1(3.0) |
  AI | 22(34.9) | - | 12(40.0) | 10(30.3) |
  SERD | 37(58.7) | - | 15(50.0) | 22(66.7) |